Corcept Falls 30% as Analysts Lift Targets and Piper Raises Bar to $173

Corcept Therapeutics has shed 30% over the past month and 6.5% in the past week alone, closing at $81.93 on November 3, a move that sits well outside the median weekly change of roughly minus 1.4% for its closest Nasdaq pharmaceutical peers. The gap between where the stock is trading and where analysts think it should trade has rarely been wider, and that tension is the central fact about CORT right now.

The Street remains firmly constructive despite the decline. Piper Sandler's David Amsellem reiterated his Overweight rating on November 4 and raised his price target to $173, up from $165, making it the most recent and most explicit statement of conviction on the name. The broader analyst picture supports that view: the consensus sits at buy, with three buy-rated analysts and a mean target of $141, implying the stock would need to nearly double from current levels to reach that figure. The bull case centres on relacorilant's commercial traction. Lifyorli generated $47.6M in its first US quarter of sales, the CHMP issued a positive opinion for the European market in 2026, and the FDA acknowledged the GRACE trial met its primary endpoint, putting a potential Cushing's syndrome approval on a six-month review clock. The bear case is narrower but pointed: Most Favored Nation pricing policy creates real uncertainty around any launch outside the US, and Wolfe Research, which downgraded to Underperform in late July with a $50 target, argues the international commercial opportunity is simply too hard to underwrite at this valuation.

Short positioning has been building through the sell-off, though it does not yet look extreme. Short interest covers 8.1% of the free float, up nearly 2% over the past week and roughly in line with October levels after a brief flush lower in mid-month. Borrowing costs have crept higher, up around 29% over the past month to 0.39%, though the absolute rate remains well within the low-cost range. Availability is ample at 1,354%, meaning the lending pool holds roughly 13.5 times as many shares as are currently borrowed, and there is no structural tightness that would create squeeze dynamics. Options traders are even less bearish: the put/call ratio has dropped to 0.48, more than one standard deviation below its 20-day average of 0.59, placing it near the bottom of its recent range. Shorts are rebuilding at the equity level while options participants are reaching for calls, not protection.

Insider activity over the past 90 days tells a more cautious story, though the detail matters. The net position is a sale of roughly 155,000 shares worth around $17.5M, but every transaction on record was executed under a pre-arranged 10b5-1 trading plan. Director James Wilson sold around 10,000 shares in mid-October at prices above $114, and the company's President of Oncology sold a similar-sized position on October 2, also under a plan. Planned sales are compensation mechanics rather than directional calls, and the trades were executed at prices well above where the stock closed this week. BlackRock added 3.4 million shares as of September 30, lifting its stake to 8.9% of the company, while State Street added 703,000 shares over the same period. AQR built a new position of 2.6 million shares. The index angle is now fully in the past: CORT was added to the S&P MidCap 400 and removed from the S&P SmallCap 600 in September, an event that required roughly $1.3B of tracker buying and is now implemented.

The company reports earnings today, November 4. The only comparable quarterly move in the history file is from July 29, when CORT rose 25.6% the following day and held most of that gain over the subsequent week. That print followed Lifyorli's first full US commercial quarter and the ROSELLA ovarian cancer data. This quarter, the question the market is likely to ask is whether Lifyorli revenue growth is holding its trajectory, and what management says about the timeline and commercial strategy for European launch given the MFN pricing environment.